Company news

Moleculin Biotech, Inc. news in 2025

Moleculin Biotech, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors

December 17, 2025

Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds

December 10, 2025

Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026

December 9, 2025

Moleculin Announces New Annamycin Collaboration in Brain Tumors

December 8, 2025

Moleculin to Participate in the Virtual Investor Closing Bell Series

November 26, 2025

Moleculin Announces Reverse Stock Split

November 26, 2025

Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented

November 13, 2025

Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill

November 12, 2025

Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting

October 30, 2025

Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin

October 29, 2025

Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer

October 23, 2025

Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin

September 25, 2025

Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial

September 9, 2025

Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia

September 8, 2025

Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds

August 28, 2025

Moleculin Issues New Positive AML Overall Survival Data:

August 27, 2025

Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

August 14, 2025

Moleculin Reports Second Quarter 2025 Financial Results and Highlights

August 13, 2025

Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment

August 6, 2025

Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin

July 30, 2025

Moleculin Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

July 22, 2025

Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships

July 17, 2025

Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans

July 9, 2025

Moleculin Announces $5.9 Million Public Offering

June 20, 2025

Moleculin Participates in Virtual Investor “What This Means” Segment

June 18, 2025

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML

June 18, 2025

Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)

June 5, 2025

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)

June 4, 2025

Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial

May 12, 2025

Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

May 7, 2025

Moleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for Annamycin

May 6, 2025

Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents

May 5, 2025

Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer

April 29, 2025

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

April 17, 2025

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

April 1, 2025

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

March 24, 2025

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

March 19, 2025

Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

March 11, 2025

Moleculin to Present at the 37th Annual ROTH Conference

March 10, 2025

Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity

March 6, 2025

Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium

March 3, 2025

Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules

February 25, 2025

Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)

February 12, 2025

Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds

February 12, 2025

Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial

February 10, 2025

Moleculin Participates in Virtual Investor "What This Means" Segment

January 26, 2025

Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026

January 7, 2025

Calls in 2025

Decks in 2025